MEDCAC mixed on cancer diagnostics

CMS's Medicare Evidence Development and Coverage Advisory Committee (MEDCAC) concluded on Wednesday that existing evidence is sufficient to confirm the clinical validity of DNA- or RNA-

Read the full 264 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE